Evaluation of new putative tumor markers for melanoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.
Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.
Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.
Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.
- Schutter, EMJ, Visser, JJ, Kamp, GJ (1992) The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy: a review of the literature. Tumor Biol 13: pp. 121-32
- Katopodis, N, Hirshaut, Y, Geller, NL, Stock, CC (1982) Lipid-associated sialic acid test for the detection of human cancer. Cancer Res 42: pp. 5270-5
- Reintgen, DS, Cruse, CW, Wells, KE, Saba, HI, Fabri, PJ (1992) The evaluation of putative tumor markers for malignant melanoma. Ann Plast Surg 28: pp. 55-9
- Moore, BW (1965) A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 19: pp. 739-44 CrossRef
- Nakajima, T, Watanabe, S, Sato, Y, Kameya, T, Shimosato, Y, Ishihara, K (1982) Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 50: pp. 912-18
- Stefansson, K, Wollmann, RL, Moore, BW (1982) Distribution of S-100 protein outside the central nervous system. Brain Res 234: pp. 309-17 CrossRef
- Fagnart, OC, Sindic, CJM, Laterre, C (1988) Particle counting immunoassay of S-100 protein in serum: possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 34: pp. 1387-91
- Springall, DR, Gu, J, Cocchia, D (1983) The value of S-100 immunostaining as a diagnostic tool in human malignant melanomas: a comparative study using S-100 and neuron-specific enolase antibodies. Virchows Arch Pathol Anat 400: pp. 331-43
- Gaynor, R, Herschman, HR, Irie, R, Jones, P, Morton, D, Cochran, A (1981) S-100 protein: a marker for human malignant melanomas?. Lancet 1: pp. 869-71
- Cho, KH, Hashimoto, K, Taniguchi, Y, Pietruk, T, Zarbo, RJ, An, T (1990) Immunohistochemical study of melanocytic nevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 66: pp. 765-71
- Kaplan, FL, Meier, P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 52: pp. 457-81
- Mantel, N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: pp. 163-70
- Peto, R, Pike, MC, Armitage, P (1997) Design and analysis of randomized trials requiring prolonged observation of each patient II. analysis and examples. Br J Cancer 35: pp. 1-39
- Cox, DR (1972) Regression models life tables. J R Stat Soc 34: pp. 187-220
- Bartolucci, AA, Fraser, MD (1977) Comparative step-upward composite tests for selecting prognostic indicators associated with survival. Biomet J 19: pp. 437-48
- Dorr, VJ, Williamson, SK, Stephans, RL (1993) An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 153: pp. 2529-37 CrossRef
- Catalona, WJ, Smith, DS, Ratliff, TL (1991) Measurement of prostate-specific antigen in serum as a screening for prostate cancer. N Engl J Med 324: pp. 1156-61
- Woolfson, K (1991) Tumor markers in cancer of the colon and rectum. Dis Colon Rectum 34: pp. 506-11 CrossRef
- Martin, EW, Cooperman, M, Carey, LC, Minton, JP (1980) Sixty second-look procedures primarily by rise in serial carcinoembryonic antigen. J Surg Res 28: pp. 389-94 CrossRef
- Reintgen, DS, Cox, C, Slingluff, CL, Seigler, HF (1992) Recurrent malignant melanoma: the identification of prognostic factors to predict survival. Ann Plast Surg 28: pp. 45-9
- Clark HB, Santa Cruz D, Hartman BK, Moore BW. S-100 protein, an immunohistochemical marker for malignant melanoma and other melanocytic lesions [Abstract].Lab Invest 1982;46:13A.
- Cochran, AJ, Wen, D-R, Herschman, HR, Gaynor, RB (1982) Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 30: pp. 295-7
- Nakajima, T, Watanabe, S, Sato, Y, Kameya, T, Shimosato, Y (1981) Immunohistochemical demonstration of S-100 protein in human malignant melanoma and pigmented nevi. Gann 72: pp. 335-6
- Stefansson, K, Wollmann, R, Jerkovic, M (1982) S-100 protein in soft-tissue tumors derived from Schwann cells and melanocytes. Am J Pathol 106: pp. 261-8
- Kahn, HJ, Baumal, R, Marks, A (1984) The value of immunohistochemical studies using antibody to S-100 protein in dermatopathology. Int J Dermatol 23: pp. 38-44
- Kirkwood JM. Present and future applications of the interferons in melanoma [Abstract]. 38th Annual Clinical Conference, Advances in the Biology and Clinical Management of Melanoma. M.D. Anderson Cancer Center, Houston, February 1995.
- Cascinelli, N (1995) Evaluation of efficacy of adjuvant rIFN-α 2A in melanoma patients with regional node metastases [Abstract 1296]. Proc Am Soc Clin Oncol 14: pp. 410-410
- Evaluation of new putative tumor markers for melanoma
Annals of Surgical Oncology
Volume 3, Issue 6 , pp 558-563
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Metastatic melanoma
- Tumor marker
- Industry Sectors
- Author Affiliations
- 1. Cutaneous Oncology Program, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 2. Division of Medical Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 3. Dianon Systems, Inc., Stratford, Connecticut, USA